7,030 Shares in Invesco Pharmaceuticals ETF $PJP Acquired by Gilpin Wealth Management LLC

Gilpin Wealth Management LLC bought a new position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 7,030 shares of the company’s stock, valued at approximately $735,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in PJP. IFP Advisors Inc raised its holdings in shares of Invesco Pharmaceuticals ETF by 31.3% in the 4th quarter. IFP Advisors Inc now owns 440 shares of the company’s stock worth $46,000 after purchasing an additional 105 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Invesco Pharmaceuticals ETF in the 4th quarter worth approximately $64,000. PNC Financial Services Group Inc. raised its holdings in shares of Invesco Pharmaceuticals ETF by 29.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,325 shares of the company’s stock worth $139,000 after purchasing an additional 300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Invesco Pharmaceuticals ETF in the 4th quarter worth approximately $167,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Invesco Pharmaceuticals ETF in the 3rd quarter worth approximately $203,000.

Invesco Pharmaceuticals ETF Price Performance

NYSEARCA PJP opened at $111.77 on Thursday. The company’s 50 day simple moving average is $106.47 and its 200 day simple moving average is $106.02. Invesco Pharmaceuticals ETF has a 12 month low of $78.77 and a 12 month high of $113.20. The company has a market capitalization of $365.49 million, a P/E ratio of 15.59 and a beta of 0.46.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.